hzn-825
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2021 (NCT04781543)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Lysophosphatidic acid receptor Edg-2ANTAGONIST
LPAR1 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05626751 | Phase 2 | Nov 4, 2022 | Horizon Pharma, Horizon Therapeutics, LLC |
| NCT05032066 | Phase 2 | Aug 25, 2021 | Horizon Therapeutics, LLC |
| NCT04781543 | Phase 2 | Apr 1, 2021 | Horizon Therapeutics, LLC |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Horizon Therapeutics, LLC | For profit | 3 | 2 | 1 | 2021 |
| Horizon Pharma | For profit | 1 | 1 | 1 | 2022 |
2 organizations
Page 1 / 1